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Although the rates of vertical transmission of
HIV in the developing world have improved to
around 3% in countries like South Africa,
resistance to antiretrovirals (ARV) used in Pre-
vention of Mother-to-Child transmission
(pMTCT) strategies may thwart such outcomes
and affect the efficacy of future ARV regimens
in mothers and children. This study conducted
in Durban, South Africa, between 2010 and
2013 found a high rate of nevirapine (NVP)
resistance among women receiving Zidovudine
(AZT) from 14 weeks gestation, single dose
nevirapine (sd NVP) at the onset of labor and a
single dose of coformulated Tenofovir/Emtrici-
tabine (TDF/FTC) postpartum. Using Sanger
sequencing, high and intermediate levels of
nevirapine (NVP) resistance were detected in
15/44 (34%) and in 1/44 (2%) of women tested,
respectively. Most subjects selected the K103N
mutation (22% (10/45) of all patients and 66%
(10/15) of those with high-level NVP resist-
ance). Such rate of NVP resistance is compara-
ble to studies where only sd NVP was used. In
conclusion, a post-partum single-dose TDF/FTC
tail does not prevent the selection of NNRTI
resistance in women receiving pre-partum ZDV
and intrapartum sd NVP to prevent mother-to-
child HIV-1 transmission. J. Med. Virol. 87:
1662–1667, 2015. # 2015 The Authors. Journal
of Medical Virology published by Wiley Periodicals, Inc.
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INTRODUCTION
Prevention of Mother-to-Child HIV-1 Transmission
(pMTCT) programs in resource-limited settings have
enabled an overall reduction in the rates of vertical
transmission to around 3% in countries like South
Africa [Moodley et al., 2013]. However selection of
antiretroviral (ARV) drug resistance during pMTCT
due to issues like poor adherence, ARV access,
complicated pMTCTs strategies and interruptions in
ARV supply remains a challenge [Paredes et al.,
2013]. It is important that these challenges be over-
come in order to preserve future treatment options
for women exposed to ARVs used for pMTCT. Resist-
ance associated with sd NVP is well documented
[Eshleman et al., 2004a; Eshleman et al., 2005; Flys
et al., 2007a] and occurs in 25% of women at 6–8
weeks postpartum [Eshleman et al., 2004b]. A meta-
analysis of studies assessing resistance to sd NVP
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found the overall risk to be 37.5% [Arrive et al.,
2007]. In addition, these drug resistant variants tend
to persist and may result in treatment failure when
the drug is re-initiated [Flys et al., 2007b; Lockman
et al., 2007; Coovadia et al., 2009]. Studies that have
assessed the optimal strategy for pMTCT in reducing
the potential for NVP resistance have investigated,
among others, Zidovudine(AZT) monotherapy accord-
ing to the ACTG 076 protocol [ACTG076, 1997], AZT
with Didanosine (DDI) [Lallemant et al., 2010] and
short course AZT and Lamivudine (3TC) [Palmer
et al., 2012].
A study by Chi et al investigated whether a single
dose of Tenofovir (TDF) with Emtricitabine (FTC)
given at delivery would reduce NVP resistance. NVP
resistance was reduced by 53% at 6 weeks post-
delivery [Chi et al., 2007]. Subsequently the strategy of
using a single dose of TDF/FTC has been included in
pMTCT guidelines in certain countries. The South
African pMTCT guidelines were revised in 2008, 2010
and 2013 (Table I). The 2010 guidelines provided ARV
prophylaxis to women not eligible for triple therapy (ie
CD4 count >350 cells/ml) .The pMTCT strategy in-
cluded antenatal AZT from 14 weeks gestation, sd
NVP at the onset of labor with 3 hourly AZT during
labor and postpartum single dose of TDF/FTC. The
aim of this study was to assess the rates of resistance
in this group of patients since resistance to NVP, AZT
or TDF/FTC will have clinical implications for women
initiating Highly Active Antiretroviral Therapy
(HAART) containing these ARVs. Although the 2013
guidelines now include the use of HAART for pMTCT
the question of resistance in this group is still relevant
for those women who have or will initiate HAART and
for other countries in the developing world using
similar strategies.
METHODS
This study was conducted at Lwazi clinic, Adding-
ton Hospital in Durban, South Africa. Full ethical
permission was obtained from the Biomedical Re-
search Ethics Committee of the University of Kwa-
Zulu-Natal (BF 069-09). Permission from the
Department of Health and management of Addington
Hospital was obtained. Ninety seven patients were
recruited. Patients with a CD4 count of >350cells/
mm3 who did not qualify for HAART were included
in the study. Full informed consent was obtained. A
blood sample for viral load was collected at baseline
and at 6 weeks post-delivery. A sample for resistance
testing was collected at 6 weeks post-delivery. In-
formation on adherence was captured at the 6 weeks
post-delivery visit where patients were asked specifi-
cally whether they received AZT and NVP during
labor and TDF/FTC post-delivery. Patients could
have answered “yes”, “no” or “unsure”. Antenatal
adherence counseling formed part of the routine
follow up. Of the 97 patients recruited, 28 patients
did not return for the 6 weeks visit, one sample was
lost, 18 patients had a viral load of <1000 copies/ml
and were excluded from resistance testing and six
samples did not amplify. Forty four samples were
included for resistance testing. Funding was provided
by the Medical Research Council and the National
Health Laboratory service Research Trust.
LABORATORY METHODS
Viral Load
Viral load testing was implemented at the Depart-
ment of Virology, University of KwaZulu-Natal, Na-
tional Health Laboratory Services. Viral loads were
performed initially using the automated Nuclisens
EasyQ1 (bioMerieux) HIV-1 assay. RNA was ex-
tracted using the Nuclisens EasyMag1 HIV-1(bio-
Merieux). The Nuclisens Easy Q1 platform was
discontinued in January 2011 and was replaced with
the Abbot m2000spTM and Abbot M2000rtTM systems
of extraction and real time amplification,
respectively.
Primers
Primers were designed using a subtype C isolate,
Genbank accession no AY772699 (http://www.ncbi.
nlm.nih.gov/nuccore/AY772699). Nested primers were
designed to cover reverse transcriptase (RT). Primer
sequences were as follows: 1855-F1 (1855–1882 in
AY772699, 2444–2470 in HXB2), 50-AGAAATTTGTG-
GAAAAAAGGCTATAGG-30, 2754-R2ON (2754–2724
in AY772699, 3343-3314 in HXB2), 50 TTTAATT-
TTCCCACTAACTTCTGTATATCA-30, 1863-F1AIN
(1863–1882 in AY772699, 2452–2476 in HXB2),
50-GTGGAAAAAAGGCTATAGGTACAGT-30, 2745-R2
(2745–2720 in AY772699, 3334–3310 in HXB2), 50-
CCCACTAACTTCTGTATATCATTGA-30.
RNA Preparation, Conventional RT-PCR and
PCR
Samples were collected in EDTA tubes and proc-
essed within 24–48hr of collection. RNA was ex-
tracted from 1ml of plasma using the Nuclisens
EasyMag1 HIV-1(bioMerieux) assay and used to
generate PCR products for Sanger sequencing. The
extracted RNA (3.75ml) was added to the RT-PCR
reaction mix (final volume of 12.5ml) containing 2
buffer, MgSO4 (5mM, final concentration of 0.6mM),
sterile water, RNAse out, forward(1855-F1) and
reverse(2754-R2ON) primers (final concentration of
0.2mM and SuperScript1 III One-Step RT PCR
(0.5ml) (Invitrogen, Carlsbad, CA). After a reverse
transcription step at 55˚C for 25min, thermocycling
was performed under the following conditions: 25
cycles of 94˚C for 2min thereafter for 30 sec, 57˚C for
30 sec, 68˚C for 30 sec and extension at 68˚C for
1min. One microlitre of the first round PCR product
was added to the second round PCR reaction mix
(final volume of 50ml) containing 10 buffer, MgS04
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(50Mm, final concentration 2mM), dNTP (10mM),
Platinum1 Taq High Fidelity enzyme (0.4ml) (Invi-
trogen), sterile water and forward (1863-F1AIN) and
reverse (2745-R2) primers (final concentration of
0.2mM) Cycling conditions were as for the first round
excluding the RT step of 55˚C for 25min. 50ml of
PCR product was available for Sanger sequencing.
Sanger Sequencing
PCR products were purified using the Exo/SAP
amplicon purification system [Werle et al., 1994].
Population sequencing was performed at Inqaba Bio-
technical Industries (Pty) Ltd in Pretoria using the
automated sequencer, ABI 3500XL genetic analyser.
(Applied Biosystems, Foster City, CA). Genotypes
were interpreted using the Geneious software (Bio-
matters Ltd. Auckland, New Zealand). Drug resistant
mutations were interpreted using the Stanford data-
base (http://hivdb.stanford.edu). To exclude sample
contamination, phylogenetic analysis was performed
by generating neighbor joining trees.
Statistical Analysis
Nonparametric methods, x2 test or Fisher’s exact
test were used as appropriate for the type of data
analyzed. SPSS (IBM, Armonk, NY) was use for all
statistical analyses.
RESULTS
There was no statistically significant difference in
the CD4 counts and viral load (baseline and 6 weeks)
between the NVP resistant group and NVP suscep-
tible groups (Table II).
The average duration of exposure to AZT in the
NVP resistant group was 15 weeks and in the NVP
susceptible group was 17 weeks with no statistically
significant difference. There was no association be-
tween the lack of intake of the stat dose of TDF/FTC
and the development of NVP resistance (P¼ 0.621).
In the NVP resistant group only one patient
reported not having received AZT in labor and one
reported not having received TDF/FTC post-delivery.
In the group without NVP resistance, three patients
were unsure whether they received AZT or TDF/FTC,
one reported not having received any ARV’s and one
reported not having received TDF/FTC.
Specific information relating to antenatal AZT
adherence was not captured for the purpose of the
study since study visits were at baseline and at
6 weeks post-delivery only. However, adherence to
AZT was discussed at the routine antenatal visits.
Of 44 patients, resistance mutations were detected
in 19 (43%) patients. All patients had a single
mutation with the exception of four patients where
dual mutations were found. (K103N and Y188C,
K103N and G190AG, A98G and G190AG and Y188C
and V90I). Sixteen (36%) patients had mutations
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patients had mutations (viz K103N, Y181C, Y188C,
Y188HY, and G190AG) associated with high level
resistance to NNRTI, in particular NVP, whilst 1
(2%) patient had K101E associated with intermediate
resistance to NNRTIs. The mutation most frequently
detected was K103N, seen in 66% (10/15) of patients
in whom a mutation conferring high-level NNRTI
resistance was detected. T69S, a mutation which
confers resistance to all NRTI’s was found in one
patient. V90I and E138A were detected in each of
two patients. These mutations are polymorphic acces-
sory mutations and do not confer resistance to
NNRTIs. No Thymidine analog mutations (TAMs) or
M184V were detected.
The frequency of mutations is indicated in
Figure 1.
DISCUSSION
In our study conducted in Durban, South Africa,
among women receiving antenatal AZT for variable
periods from 14 weeks gestation, sd NVP at the onset
of labor and sd TDF/FTC postpartum, high level NVP
resistance was detected in 34% of patients. Although
the average risk of NVP resistance with the use of sd
NVP is 35.7% [Arrive et al., 2007] our detection rate
is still high considering that antepartum AZT and
postpartum TDF/FTC were included in the pMTCT
strategy and that the mean baseline CD4 counts
were relatively high.
A study by Chi et al [2007], conducted in Zambia
found that a postpartum single-dose of TDF/FTC
reduced NNRTI resistance by 53% at 6 weeks in
women receiving pre-partum short course AZT and
intrapartum sd NVP. The pMTCT strategy used is
very similar to that described in our study. However,
despite the use of TDF/FTC and pre-partum AZT, we
still detected high rates of NNRTI resistance. In
comparison to the study by Chi et al, AZT was
administered earlier in pregnancy in our study (as
early as 14 weeks gestation compared to 32 weeks)
and the mean log viral load at 6 weeks was lower,
(3.87 compared to 4.40), factors which should have
reduced NNRTI resistance but was not found in our
study. There are a number of reasons that may
explain the high rate of NVP resistance detected
including poor adherence to this complex pMTCT
strategy, previous exposure to sd NVP and higher
rates of transmitted drug resistance (TDR) in Kwa-
Zulu-Natal. In Zambia in 2007, there probably was
not as high levels of TDR (NNRTI) as we are seeing
in KZN and the effect of NVP in successive pregnan-
cies may not have been that apparent.
Although adherence to the regimen was docu-
mented at the 6 week visit by self-reporting this
method of assessment of adherence is not very
accurate [Brouwer, 2011] and given the complex
pMTCT strategy, poor adherence may have contrib-
uted to the higher rates of resistance detected. A
study in KZN, among patients failing first line
therapy found ARV resistance in 83% of patients
where the majority (82.7%) of patients reported >
95% adherence [Marconi, 2008].
Previous exposure to NVP in successive pregnan-
cies may result in higher rates of NVP resistance
[Martinson, 2009].Given the length of time that sd
NVP has been used for pMTCT in SA it is likely that
a proportion of women may have had prior exposure
to sd NVP.
The 2012 WHO report on TDR indicates that the
rate of transmitted resistance in KwaZulu-Natal
increased from <5% (low) in 2005 to 5–15% (moder-
ate) in 2010. The rate in 2010 is much higher than
that of Gauteng, South Africa. Factors such as poor
adherence, interruptions in ARV supply, population
level based rates of viral load suppression and lost to
follow up are among some of the issues that could be
contributing to a higher rate of transmitted resist-
ance in KwaZulu-Natal although these factors are
not unique to KZN alone [WHO, 2012a]. A 2013
TABLE II. Patient Characteristics as Per Nevirapine Resistant Versus Susceptible Groups
Parameter Resistant (n¼ 16) Susceptible (n¼28) P-value
Mean CD4 cells/mm3 480 510 0.871
Viral load (log)
Baseline 3.44 3.2 0.893
6 weeks 3.87 3.93 0.598
Average duration of exposure to AZT 15 weeks 17 weeks 0.451
Fig. 1. Percentage of mutations detected in 44 women
exposed to pMTCT (antepartum AZT, intrapartum sdNVP and
postpartum sd TDF/FTC).
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study in Durban among women being screened for
HIV prevention trials found baseline resistance of
7.4% confirming higher levels of TDR in KZN [Par-
ikh, 2013].
Besides higher rates of TDR, perhaps more impor-
tantly and pertinent to the pMTCT program is that
the most common TDR mutations detected are those
conferring NNRTI resistance, in particular, K103N.
The WHO report (2012) indicates that the rate of
NNRTI resistance in the African region has increased
from 1% in 2003 to 6.4% in 2010 with K103N/S being
the most commonly detected mutation [WHO, 2012a].
A pooled analysis of sequences submitted to genbank
from TDR surveys conducted in SA over 10 years also
found K103N followed by Y181C to be the most
common TDR mutation in SA [Manasa, 2012]. The
development of NVP resistance after exposure to sd
NVP may feed the increasing pool of TDR which
could, in turn, compromise first line NNRTI-contain-
ing ART.
There have also been higher rates of NVP resistance
reported in subtype C [Flys et al., 2006]. Eshleman
et al compared the rates of NVP resistance in subtypes
A, D, and C. The number of women with NVP
resistance was much higher in subtype C (69.2%)
compared to subtype A (19.4%) and D (36.1%). [Eshle-
man et al., 2005] Furthermore, using LigAmp to detect
minority K103N variants, higher levels of K103N were
detected in subtype C compared to A and D [Flys et al.,
2006]. The role of subtype C may be a contributor but
does not by itself explain the high rates of resistance
detected in this study since other studies assessing
ARV drug resistance after similar pMTCT strategies
in South Africa did not find as high rates of NVP
resistance [van Zyl, 2008].
The use of sd NVP is problematic for both the
mother and her baby. The development of NNRTI
resistance after exposure to sd NVP can lead to poor
clinical response to NNRTI containing regimens in
the mother [Lockman et al., 2007; Stringer et al.,
2010], transmitted NNRTI resistance to the infected
infant [Micek et al., 2014] and poor clinical response
to NNRTI-containing ART in the infant [Musiime
et al., 2009; Lehman et al., 2012]. High rates of NVP
resistance in infants exposed to sd NVP in South
Africa have been reported [Martinson, 2007; Hunt
et al., 2011].
The study did not detect TAMs consistent with
other studies investigating AZT resistance used in
the pMTCT context where either no or low level
TAMS were detected [Coffie, 2008; van Zyl, 2008]. In
addition, no K65R mutation associated with resist-
ance to TDF was observed.
The limitations of this study include the lack of
baseline resistance information, the variable timing
of the 6 week visit since patients may have returned
earlier or later to the clinic depending on logistical
factors and the lack of adherence information regard-
ing antepartum AZT. In addition, the true prevalence
of resistance mutations may be under-estimated since
Sanger sequencing will only detect mutations that
are present in at least 20% of the HIV quasisispecies.
Thus more sensitive, next generation sequencing
tools are required to assess HIV minority variants.
The pMTCT strategy described in this study is
similar to that of the World Health Organisation
(WHO) Option A [WHO, 2012b], with the exception of
a stat dose TDF/FTC instead of 7 days of AZT/3TC to
cover the NVP tail. Given the high rate of NVP
resistance despite antepartum AZT and postpartum
TDF/FTC, Option B [WHO, 2012b] and Bþ[WHO,
2012b] need to be considered to optimize treatment
options for patients initiating ART after exposure to
pMTCT. HAART is superior to AZT (with or without
sd NVP) for pMTCT resulting in improved pMTCT
and HIV-free survival [Dryden-Peterson et al., 2011].
Although the South African pMTCT guidelines of
2013 moved to Option B (with Option Bþ to be
implemented on 1st January 2015), similar strategies
are still being used in other developing countries. In
addition, the clinical impact of efavirenz containing
first line treatment in women exposed to such
pMTCT strategies remains to be seen.
In conclusion, in this resistance study conducted
among pMTCT recipients receiving pre-partum AZT,
intrapartum sd NVP and post-partum single-dose
TDF/FTC, high rates of NVP resistance was detected,
in particular K103N. Whether this is attributable to
poor adherence, higher levels of transmitted resist-
ance, previous exposure to sd NVP or the association
of K103N with subtype C, sd NVP, although simple
and effective for pMTCT, still remains problematic.
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